Log in

Start Your Membership Now

On June 26, 2019, the Louisiana Department of Health (DOH) and the Louisiana Department of Corrections (DOC) launched a new hepatitis C payment model with Asegua Therapeutics, LLC, a subsidiary of Gilead Sciences, Inc. The Centers for Medicare & Medicaid Services (CMS) approved a Medicaid State Plan Amendment (SPA) to allow the state to implement a modified subscription arrangement in which the state will pay Asegua Therapeutics a monthly rate to provide an unrestricted amount of Asegua’s direct-acting antiviral, the authorized generic of Epclusa®. The medication will be used to treat Medicaid and DOC populations. The SPA allows . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: